aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma (ATYR) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to an Item 2.02 Form 8-K. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across 10/08/2025 and 10/09/2025 at weighted average prices of $0.898 and $0.9414 respectively. After these transactions the reporting person beneficially owned 1,413,023 shares indirectly through trusts and a prototype PSP vehicle. The filings note share purchase price ranges from $0.8536 to $0.95 for the first lot and $0.93 to $0.95 for the second, and identify ownership via the Paul Schimmel Prototype PSP and the Schimmel Revocable Trust.
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.